Ticker,Trial,NCT_ID,org_study_id,organization_name,Organization Class,Overall Status,Study Type,Phases,Allocation,Intervention Model,Primary Purpose,Enrollment Count,Enrollment Type,Healthy Volunteers,Sex,Minimum Age,Maximum Age,Standardized Ages,IPD Sharing,Start Date,End Date,Price 180 Days Before,End Price
JNJ,COVID-19 Vaccine Trial (Ad26.COV2.S),NCT04505722,VAC31518COV3001,Janssen Research & Development LLC,Industry,Completed,Interventional,Phase 3,Randomized,Parallel Assignment,Prevention,43783,Actual,No,All,18 Years,N/A,"Adult, Older Adult",Yes,2020-09-01,2021-02-01,142.00999450683594,162.7100067138672
JNJ,Stelara (Ustekinumab) for Crohn's Disease,NCT01369342,CRD3001,Janssen Research & Development LLC,Industry,Completed,Interventional,Phase 3,Randomized,Parallel Assignment,Treatment,961,Actual,No,All,18 Years,N/A,"Adult, Older Adult",Yes,2013-03-01,2016-06-01,67.26000213623047,112.77999877929688
MRK,Keytruda (Pembrolizumab) for Melanoma,NCT01866319,KEYNOTE-006,Merck Sharp & Dohme LLC,Industry,Completed,Interventional,Phase 3,Randomized,Parallel Assignment,Treatment,834,Actual,No,All,18 Years,N/A,"Adult, Older Adult",Yes,2020-10-01,2021-12-01,76.63167572021484,74.44000244140625